Compare
Qiagen N.V. vs Halozyme Therapeutics, Inc. vs Repligen Corp vs ADMA Biologics, Inc.
| Latest fiscal year | Qiagen N.V. QGEN | Halozyme Therapeutics, Inc. HALO | Repligen Corp RGEN | ADMA Biologics, Inc. ADMA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.09B | $1.40B | $738.26M | $510.17M |
| Revenue growth (YoY) | +5.7% | +37.6% | +16.4% | +19.6% |
| Gross margin | 62.2% | 83.6% (computed) | 52.3% (computed) | 57.4% |
| Operating margin | 22.3% | 33.6% | 7.5% | 37.5% |
| Net margin | 20.3% | 22.7% | 6.6% | 28.8% |
| Net income | $424.88M | $316.89M | $48.89M | $146.93M |
| EPS (Diluted) | $1.94 | $2.56 | $0.86 | $0.60 |
| Operating cash flow | $654.33M | $651.56M | $117.42M | $50.40M |
| Free cash flow | $453.28M | $644.59M | $93.90M | $27.82M |
| Cash & equivalents | $839.00M | $133.82M | $566.02M | $87.63M |
| Total assets | $6.28B | $2.53B | $2.95B | $624.24M |
| Total liabilities | n/a | $2.48B | $843.57M | $146.92M |
| Shareholders' equity | $3.78B | $48.81M | $2.11B | $477.32M |
| Return on year-end equity | 11.2% | 649.2% | 2.3% | 30.8% |
| Shares outstanding | n/a | 117.78M | 56.33M | 237.87M |
Revenue, most recent five fiscal years
| Fiscal year | Qiagen N.V. | Halozyme Therapeutics, Inc. | Repligen Corp | ADMA Biologics, Inc. |
|---|---|---|---|---|
| Latest | $2.09B Ended 2025-12-31 | $1.40B Ended 2025-12-31 | $738.26M Ended 2025-12-31 | $510.17M Ended 2025-12-31 |
| 1 year earlier | $1.98B Ended 2024-12-31 | $1.02B Ended 2024-12-31 | $634.44M Ended 2024-12-31 | $426.45M Ended 2024-12-31 |
| 2 years earlier | $1.97B Ended 2023-12-31 | $829.25M Ended 2023-12-31 | $632.36M Ended 2023-12-31 | $258.21M Ended 2023-12-31 |
| 3 years earlier | $2.14B Ended 2022-12-31 | $660.12M Ended 2022-12-31 | $801.54M Ended 2022-12-31 | $154.08M Ended 2022-12-31 |
| 4 years earlier | $2.25B Ended 2021-12-31 | $443.31M Ended 2021-12-31 | $670.53M Ended 2021-12-31 | $80.94M Ended 2021-12-31 |